BACKGROUND: The effects of pimobendan on left atrial pressure (LAP) in dogs with mitral valve disease (MR) have not been documented in a quantitative manner. OBJECTIVE: The objective was to document and study the short-term effects of pimobendan on LAP and echocardiographic parameters in MR dogs. ANIMALS: Eight healthy Beagle dogs weighing 10.0-14.7 kg (3 males and 5 females; aged 2 years) were used. METHODS: Experimental, cross-over, and interventional study. Dogs with surgically induced MR received pimobendan at either 0.25 mg/kg or 0.50 mg/kg p.o. q12h for 7 days and then, after a 7-day wash-out period, the other dosage. LAP was measured for 30 minutes at baseline and again on days 1, 2, 4, and 7 of pimobendan administration. RESULTS: Mean LAP was significantly decreased after the administration of 0.25 mg/kg (15.81 ± 5.44 mmHg to 12.67 ± 5.71 mmHg, P < .001) and 0.50 mg/kg (15.76 ± 5.45 mmHg to 10.77 ± 5.23 mmHg, P < .001). Also, the 0.50 mg/kg group led to a significantly lower LAP (P < .01) compared with the 0.25 mg/kg group. Significant reduction was seen for the first time 4 days after the administration of 0.25 mg/kg and a day after the administration of 0.50 mg/kg. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan decreased LAP in a dose-dependent manner in dogs with acute MR caused by experimental chordal rupture. This study did not evaluate adverse effects of high-dose pimobendan, and additional studies in clinical patients are warranted.
BACKGROUND: The effects of pimobendan on left atrial pressure (LAP) in dogs with mitral valve disease (MR) have not been documented in a quantitative manner. OBJECTIVE: The objective was to document and study the short-term effects of pimobendan on LAP and echocardiographic parameters in MRdogs. ANIMALS: Eight healthy Beagle dogs weighing 10.0-14.7 kg (3 males and 5 females; aged 2 years) were used. METHODS: Experimental, cross-over, and interventional study. Dogs with surgically induced MR received pimobendan at either 0.25 mg/kg or 0.50 mg/kg p.o. q12h for 7 days and then, after a 7-day wash-out period, the other dosage. LAP was measured for 30 minutes at baseline and again on days 1, 2, 4, and 7 of pimobendan administration. RESULTS: Mean LAP was significantly decreased after the administration of 0.25 mg/kg (15.81 ± 5.44 mmHg to 12.67 ± 5.71 mmHg, P < .001) and 0.50 mg/kg (15.76 ± 5.45 mmHg to 10.77 ± 5.23 mmHg, P < .001). Also, the 0.50 mg/kg group led to a significantly lower LAP (P < .01) compared with the 0.25 mg/kg group. Significant reduction was seen for the first time 4 days after the administration of 0.25 mg/kg and a day after the administration of 0.50 mg/kg. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan decreased LAP in a dose-dependent manner in dogs with acute MR caused by experimental chordal rupture. This study did not evaluate adverse effects of high-dose pimobendan, and additional studies in clinical patients are warranted.
Authors: Marco Baron Toaldo; Giovanni Romito; Carlo Guglielmini; Alessia Diana; Nazzareno G Pelle; Barbara Contiero; Mario Cipone Journal: J Vet Intern Med Date: 2018-03-23 Impact factor: 3.333
Authors: Bruce W Keene; Clarke E Atkins; John D Bonagura; Philip R Fox; Jens Häggström; Virginia Luis Fuentes; Mark A Oyama; John E Rush; Rebecca Stepien; Masami Uechi Journal: J Vet Intern Med Date: 2019-04-11 Impact factor: 3.333
Authors: Fabio Sarcinella; Joao Neves; Thomas W Maddox; Hannah M Hodgkiss-Geere; Elizabeth F Bode; Joanna Dukes-McEwan Journal: Open Vet J Date: 2019-12-31
Authors: Carol Reinero; Lance C Visser; Heidi B Kellihan; Isabelle Masseau; Elizabeth Rozanski; Cécile Clercx; Kurt Williams; Jonathan Abbott; Michele Borgarelli; Brian A Scansen Journal: J Vet Intern Med Date: 2020-02-17 Impact factor: 3.333